Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report Rafal Dziadziuszko, MD, PhD,

Slides:

Advertisements

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer? Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,

Rafal Dziadziuszko, MD, PhD, Anh T

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients.

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations Rafael Caparica, MD,

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Electronic Updates for JTO Readers

How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples Takahiro Nakajima,

Estrogen Receptor (ER) and Epidermal Growth Factor Receptor (EGFR) as Targets for Dual Lung Cancer Therapy: Not Just a Case? Monica Giovannini, MD, Carmen.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor.

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Chromosomal Abnormalities in Non-Small Cell Lung Carcinomas and in Bronchial Epithelia of High-Risk Smokers Detected by Multi-Target Interphase Fluorescence.

Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004.

Activity of Gefitinib in a Non–Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations Alessandro Morabito, MD, Raffaele Costanzo,

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

MET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization Serena Varesano, PhD, Sandra Salvi, PhD, Simona Boccardo, PhD, Jean.

Role of Chromosome 3q Amplification in Lung Cancer

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib Lela E. Buckingham, PhD, John S. Coon, MD,

Erratum Journal of Thoracic Oncology

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method.

Amplification of MET in a Patient with Malignant Pleural Mesothelioma

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

First Case of A859T Epidermal Growth Factor Receptor Mutation Responding to Erlotinib Laureline Le Maignan, BM, Delphine Mirebeau-Prunier, MD, PhD, Laurent.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Shengxiang Ren, MD, PhD, Fred.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Robert Comis, MD, The Passing of a “Lung Man”

Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma Motoki Yano, MD, PhD, Hidefumi.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report Rafal Dziadziuszko, MD, PhD, Anna Siemiątkowska, MSc, Janusz Limon, MD, PhD, Witold Rzyman, MD, PhD, Jacek Jassem, MD, PhD, Paul A. Bunn, MD, Marileila Varella-Garcia, PhD, Fred R. Hirsch, MD, PhD Journal of Thoracic Oncology Volume 2, Issue 1, Pages 91-92 (January 2007) DOI: 10.1016/S1556-0864(15)30026-5 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Microscopic and molecular characteristics of the primary tumor. Nonmucinous bronchioalveolar carcinoma (A) (x200) with strong epidermal growth factor receptor (EGFR) protein expression (B) (DAKO Pharm Dx staining kit, x200), EGFR gene amplification (C) (hybridization with the LSI EGFR SpectrumOrange/CEP SpectrumGreen Probe, Vysis, Abbott Molecular), high HER2 gene copy number (D) (hybridization with the PathVysion HER-2 DNA Probe Kit, Vysis, Abbott Molecular) and EGFR exon 19 E746_A750 deletion (E) (sequencing analyzed in Genetic Analyzer ABI PRISM 310). Journal of Thoracic Oncology 2007 2, 91-92DOI: (10.1016/S1556-0864(15)30026-5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions